ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
A distinct pathologic entity (ALK+ lymphoma) that is characterized by expression of the
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous
group of CD30+ anaplastic large-cell lymphomas. Information on clinical findings and
treatment outcome of ALK+ lymphoma is still limited, and no data are available concerning
the value of the International Prognostic Index when applied to this homogeneous disease
entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed …
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous
group of CD30+ anaplastic large-cell lymphomas. Information on clinical findings and
treatment outcome of ALK+ lymphoma is still limited, and no data are available concerning
the value of the International Prognostic Index when applied to this homogeneous disease
entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed …
[PDF][PDF] ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
LF Pelicci, MF Martelli, A Santucci, GV Wolf-Peeters… - Blood, 1999 - academia.edu
A distinct pathologic entity (ALK lymphoma) that is characterized by expression of the
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous
group of CD30 anaplastic large-cell lymphomas. Information on clinical findings and
treatment outcome of ALK lymphoma is still limited, and no data are available concerning
the value of the International Prognostic Index when applied to this homogeneous disease
entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed …
anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous
group of CD30 anaplastic large-cell lymphomas. Information on clinical findings and
treatment outcome of ALK lymphoma is still limited, and no data are available concerning
the value of the International Prognostic Index when applied to this homogeneous disease
entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed …
以上显示的是最相近的搜索结果。 查看全部搜索结果